Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma.

Ryunosuke NakagawaKouji IzumiRen ToriumiShuhei AoyamaTaiki KamijimaHiroshi KanoTomoyuki MakinoRenato NaitoHiroaki Iwamoto Hiroshi Yaegashi Shohei KawaguchiKazuyoshi ShigeharaTakahiro NoharaAtsushi Mizokami

Published in: Japanese journal of clinical oncology (2024)

Biweekly administration of EV may be safer without compromising therapeutic efficacy than the standard schedule.

Keyphrases